- ISIN
- US3984384087
- CUSIP
- 398438408
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- IPO Date
- May 17, 2006
Highlights
- Market Cap
- $4.95B
- Enterprise Value
- $15.89B
- EPS (TTM)
- €0.61
- PE Ratio
- 10.46
- PEG Ratio
- 0.17
- Total Revenue (TTM)
- €7.45B
- Gross Profit (TTM)
- €2.81B
- EBITDA (TTM)
- €1.56B
- Year Range
- $7.26 - $11.14
- ROA (TTM)
- 2.07%
- ROE (TTM)
- 7.61%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GRFS Performance Chart
Grifols, S.A. (GRFS) is down 22.1% since the beginning of the year. At $7 per share, GRFS is trading 34.6% below its 52-week high of $11. Investors who bought $1,000 worth of GRFS shares 5 years ago would now be looking at an investment worth $427.
Loading charts...
Returns By Period
Grifols, S.A. (GRFS) has returned -22.14% so far this year and -15.59% over the past 12 months. Over the last ten years, GRFS has returned -6.28% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Grifols, S.A.
- 1D
- -1.62%
- 1M
- -8.77%
- YTD
- -22.14%
- 6M
- -19.82%
- 1Y
- -15.59%
- 3Y*
- -6.06%
- 5Y*
- -15.65%
- 10Y*
- -6.28%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
GRFS Monthly Returns History
Based on dividend-adjusted daily data since Jun 2, 2011, GRFS's average daily return is +0.04%, while the average monthly return is +0.70%. At this rate, an investment would double in approximately 8.3 years.
Historically, 50% of months were positive and 50% were negative. The best month was Nov 2022 with a return of +29.2%, while the worst month was Jan 2024 at -30.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 4 months.
On a daily basis, GRFS closed higher 49% of trading days. The best single day was Mar 8, 2024 with a return of +24.8%, while the worst single day was Jan 9, 2024 at -21.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.07% | -1.62% | -11.87% | 2.74% | -4.73% | -7.26% | -22.14% | ||||||
| 2025 | -7.39% | 22.50% | -15.76% | -2.25% | 19.57% | 8.78% | 18.36% | -5.25% | -0.10% | -5.92% | -5.55% | 5.65% | 27.79% |
| 2024 | -30.45% | -6.59% | -11.05% | -3.74% | 11.35% | -11.94% | 18.48% | 25.03% | -4.93% | -2.14% | -19.56% | 6.44% | -35.64% |
| 2023 | 7.18% | -4.94% | -14.90% | 1.22% | 10.46% | 11.17% | 19.10% | -13.20% | -3.48% | -11.49% | 19.78% | 19.30% | 36.00% |
| 2022 | 4.54% | 5.28% | -5.50% | -8.13% | 20.04% | -7.76% | -25.25% | -12.50% | -20.72% | 2.44% | 29.16% | 4.29% | -24.31% |
| 2021 | -4.12% | -8.03% | 6.33% | 2.08% | -0.91% | 1.29% | -12.33% | -4.73% | 0.83% | -10.27% | -18.15% | 4.66% | -37.82% |
Benchmark Metrics
Grifols, S.A. has an annualized alpha of -0.70%, beta of 0.78, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since June 02, 2011.
- This stock participated in 106.70% of S&P 500 Index downside but only 65.49% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -0.70%
- Beta
- 0.78
- R²
- 0.13
- Upside Capture
- 65.49%
- Downside Capture
- 106.70%
Return for Risk
Risk / Return Rank
GRFS ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Grifols, S.A. (GRFS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GRFS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.52 | ||
| Sortino ratioReturn per unit of downside risk | -3.27 | ||
| Omega ratioGain probability vs. loss probability | 0.94 | 1.37 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.49 | 2.78 | -3.27 |
| Martin ratioReturn relative to average drawdown | -0.89 | 12.44 | -13.33 |
Dividends
Dividend History
Grifols, S.A. provided a 2.41% dividend yield over the last twelve months, with an annual payout of $0.18 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.18 | $0.18 | $0.00 | $0.00 | $0.00 | $0.36 | $0.15 | $0.36 | $0.43 | $0.28 | $0.27 | $0.33 |
Dividend yield | 2.41% | 1.88% | 0.00% | 0.00% | 0.00% | 3.20% | 0.83% | 1.55% | 2.32% | 1.24% | 1.67% | 2.01% |
Monthly Dividends
The table displays the monthly dividend distributions for Grifols, S.A.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.18 | $0.00 | $0.00 | $0.00 | $0.00 | $0.18 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.36 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.36 |
Dividend Yield & Payout
Dividend Yield
Grifols, S.A. has a dividend yield of 2.41%, which is quite average when compared to the overall market.
Payout Ratio
Grifols, S.A. has a payout ratio of 30.71%, which is quite average when compared to the overall market. This suggests that Grifols, S.A. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Grifols, S.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Grifols, S.A. was 78.01%, occurring on Mar 6, 2024. The portfolio has not yet recovered.
The current Grifols, S.A. drawdown is 70.24%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -78.01%Mar 2024 | 4y 12d | — | 6y 4moFeb 2020 - now |
2011 bear market2011 | -38.75%Nov 2011 | 4mo 6d | 2mo 9d | 6mo 15dJul 2011 - Feb 2012 |
2016 bear market2016 | -37.15%Jan 2016 | 1y 7mo | 1y 4mo | 3y 12dJun 2014 - Jun 2017 |
Rate-hike selloffLate 2018 | -28.74%Dec 2018 | 6mo 14d | 1y 14d | 1y 6moJun 2018 - Jan 2020 |
2018 correction2018 | -19.20%Apr 2018 | 2mo 26d | 1mo 18d | 4mo 14dJan 2018 - Jun 2018 |
Drawdown Indicators
| GRFS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -78.01% | -56.78% | -21.23% |
Max Drawdown (1Y)Largest decline over 1 year | -32.22% | -9.10% | -23.12% |
Max Drawdown (3Y)Largest decline over 3 years | -52.68% | -18.90% | -33.78% |
Max Drawdown (5Y)Largest decline over 5 years | -69.29% | -25.43% | -43.86% |
Max Drawdown (10Y)Largest decline over 10 years | -78.01% | -33.92% | -44.09% |
Current DrawdownCurrent decline from peak | -70.24% | -1.80% | -68.44% |
Average DrawdownAverage peak-to-trough decline | -31.83% | -10.71% | -21.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.58% | 2.03% | +15.55% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Grifols, S.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Grifols, S.A. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for GRFS, comparing it with other companies in the Drug Manufacturers - General industry. Currently, GRFS has a P/E ratio of 10.5. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for GRFS compared to other companies in the Drug Manufacturers - General industry. GRFS currently has a PEG ratio of 0.2. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GRFS relative to other companies in the Drug Manufacturers - General industry. Currently, GRFS has a P/S ratio of 0.6. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GRFS in comparison with other companies in the Drug Manufacturers - General industry. Currently, GRFS has a P/B value of 0.8. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GRFS
Add Grifols, S.A. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GRFS